Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Retained Earnings (2016 - 2025)

Tvardi Therapeutics' Retained Earnings history spans 13 years, with the latest figure at $8000.0 for Q4 2025.

  • On a quarterly basis, Retained Earnings rose 100.01% to $8000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $8000.0, a 100.01% increase, with the full-year FY2025 number at $8000.0, up 100.01% from a year prior.
  • Retained Earnings hit $8000.0 in Q4 2025 for Tvardi Therapeutics, up from -$103.2 million in the prior quarter.
  • Over the last five years, Retained Earnings for TVRD hit a ceiling of $12000.0 in Q1 2021 and a floor of -$760.5 million in Q1 2025.
  • Historically, Retained Earnings has averaged -$377.5 million across 5 years, with a median of -$494.6 million in 2021.
  • Biggest five-year swings in Retained Earnings: tumbled 53589400.0% in 2022 and later skyrocketed 100.01% in 2025.
  • Tracing TVRD's Retained Earnings over 5 years: stood at -$480.8 million in 2021, then dropped by 17.78% to -$566.2 million in 2022, then surged by 99.95% to -$260000.0 in 2023, then crashed by 35375.38% to -$92.2 million in 2024, then skyrocketed by 100.01% to $8000.0 in 2025.
  • Business Quant data shows Retained Earnings for TVRD at $8000.0 in Q4 2025, -$103.2 million in Q3 2025, and -$97.6 million in Q2 2025.